Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE.
Hirano M, Martí R, Casali C, Tadesse S, Uldrick T, Fine B, Escolar DM, Valentino ML, Nishino I, Hesdorffer C, Schwartz J, Hawks RG, Martone DL, Cairo MS, DiMauro S, Stanzani M, Garvin JH Jr, Savage DG. Hirano M, et al. Among authors: hawks rg. Neurology. 2006 Oct 24;67(8):1458-60. doi: 10.1212/01.wnl.0000240853.97716.24. Epub 2006 Sep 13. Neurology. 2006. PMID: 16971696 Free PMC article.
Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.
Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, George D, Bradley MB, Harrison L, Petrillo K, Schwartz J, Foley S, Hawks R, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Biol Blood Marrow Transplant. 2013 Apr;19(4):552-61. doi: 10.1016/j.bbmt.2012.12.005. Epub 2012 Dec 16. Biol Blood Marrow Transplant. 2013. PMID: 23253557 Free article.
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E, Garvin J, Bradley MB, Bhatia M, Satwani P, George D, Del Toro G, Hawks R, Wolownik K, Foley S, Cheung YK, Schwartz J, van de Ven C, Baxter-Lowe LA, Cairo MS. Waxman IM, et al. Pediatr Transplant. 2009 Jun;13(4):464-74. doi: 10.1111/j.1399-3046.2008.01000.x. Epub 2008 Sep 10. Pediatr Transplant. 2009. PMID: 18785912
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9. Biol Blood Marrow Transplant. 2012. PMID: 22079471 Free article. Clinical Trial.
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.
Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, Baxter-Lowe LA, Schwartz J, Qualter E, Hawks R, Wolownik K, Foley S, Militano O, Leclere J, Cheung YK, Cairo MS. Bradley MB, et al. Bone Marrow Transplant. 2007 Oct;40(7):621-31. doi: 10.1038/sj.bmt.1705785. Epub 2007 Jul 30. Bone Marrow Transplant. 2007. PMID: 17660841
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS. Roman E, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s. doi: 10.1158/1078-0432.CCR-1004-0018. Clin Cancer Res. 2005. PMID: 16203817 Clinical Trial.
A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients.
Unal E, Yen C, Saiman L, George D, Della-Latta P, van de Ven C, Morris E, Bradley MB, Del Toro G, Garvin J, Bhatia M, Schwartz J, Satwani P, Roman E, Cooney E, Wolownik K, Hawks R, Foley S, Cairo MS. Unal E, et al. Biol Blood Marrow Transplant. 2006 Nov;12(11):1188-97. doi: 10.1016/j.bbmt.2006.07.006. Biol Blood Marrow Transplant. 2006. PMID: 17085312 Free article.
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Bone Marrow Transplant. 1998 Oct;22(7):661-7. doi: 10.1038/sj.bmt.1701408. Bone Marrow Transplant. 1998. PMID: 9818693
Outcomes of unrelated cord blood transplantation in pediatric recipients.
Styczynski J, Cheung YK, Garvin J, Savage DG, Billote GB, Harrison L, Skerrett D, Wolownik K, Wischhover C, Hawks R, Bradley MB, Del Toro G, George D, Yamashiro D, van de Ven C, Cairo MS. Styczynski J, et al. Bone Marrow Transplant. 2004 Jul;34(2):129-36. doi: 10.1038/sj.bmt.1704537. Bone Marrow Transplant. 2004. PMID: 15107815 Clinical Trial.
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS. Bhatia M, et al. Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5. Bone Marrow Transplant. 2014. PMID: 24797180 Clinical Trial.
18 results